[1]
|
Bhardwaj, S.S. and Chalasani, N. (2007) Lipid-Lowering Agents that Cause Drug-Induced Hepatotoxicity. Clinics in Liver Disease, 11, 597-613. https://doi.org/10.1016/j.cld.2007.06.010
|
[2]
|
Omagari, K., Kadokawa, Y., Masuda, J., Egawa, I., Sawa, T., Hazama, H., et al. (2002) Fatty Liver in Non-Alcoholic-Overweight Japanese Adults: Incidence and Clinical Characteristics. Journal of Gastroenterology and Hepatology, 17, 1098-1105. https://doi.org/10.1046/j.1440-1746.2002.02846.x
|
[3]
|
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. (2008) Genetic Variation in PNPLA3 Confers Susceptibility to Non-Alcoholic Fatty Liver Disease. Nature Genetics, 40, 1461-1465. https://doi.org/10.1038/ng.257
|
[4]
|
Thurman, R.G. (1998) Mechanisms of Hepatic Toxicity. II. The Alcoholic Liver Injury Involves the Activation of Kupffer Cells by the Endotoxin. American Journal of Physiology, 275, G605-G611. https://doi.org/10.1152/ajpgi.1998.275.4.G605
|
[5]
|
Loomba, R. and Sanyal, A.J. (2013) The Global NAFLD Epidemic. Nature Reviews Gastroenterology & Hepatology, 10, 686-690. https://doi.org/10.1038/nrgastro.2013.171
|
[6]
|
Struben, V.M., Hespenheide, E.E. and Caldwell, S.H. (2000) Non-Alcoholic Steatohepatitis and Cryptogenic Cirrhosis in Kindreds. The American Journal of Medicine, 108, 9-13. https://doi.org/10.1016/S0002-9343(99)00315-0
|
[7]
|
Violi, F., Calvieri, C. and Ferro, D. (2013) Statins as Antithrombotic Drugs. Circulation, 127, 251-257. https://doi.org/10.1161/CIRCULATIONAHA.112.145334
|
[8]
|
Pelli, N., Setti, M., Ceppa, P., Toncini, C. and Indiveri, F. (2003) Autoimmune Hepatitis Revealed by Atorvastatin. European Journal of Gastroenterology & Hepatology, 15, 921-924. https://doi.org/10.1097/00042737-200308000-00014
|
[9]
|
Caldwell, S.H., Zaidman, J.S. and Hespenheide, E.E. (2003) The Liver and Statin Drug Therapy: Uncertain Navigation in the Sea of Risk-Benefits. Pharmacoepidemiology and Drug Safety, 12, 303-306. https://doi.org/10.1002/pds.833
|
[10]
|
Ma, P.T., Gil, G., Sudhof, T.C., Bilheimer, D.W., Goldstein, J.L. and Brown, M.S. (1986) Mevinolin, an Inhibitor of Cholesterol Synthesis, Induces mRNA for Low-Density Lipoprotein Receptor in Livers of Hamsters and Rabbits. Proceedings of the National Academy of Sciences of the United States of America, 83, 8370-8374. https://doi.org/10.1073/pnas.83.21.8370
|
[11]
|
Rehm, J., Taylor, B., Mohapatra, S., Irving, H., Baliunas, D. and Patra, J. (2010) Alcohol as a Risk Factor for Liver Cirrhosis: A Systematic Review and Meta-Analysis. Drug and Alcohol Review, 29, 437-445. https://doi.org/10.1111/j.1465-3362.2009.00153.x
|
[12]
|
Shieh, K., Gilchrist, J.M. and Promrat, K. (2010) Frequency, and Predictors of Non-Alcoholic Fatty Liver Disease in the Myotonic Dystrophy. Muscle & Nerve, 41, 197-201. https://doi.org/10.1002/mus.21484
|
[13]
|
Angulo, P. (2002) Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 346, 1221-1231. https://doi.org/10.1056/NEJMra011775
|
[14]
|
Daniel, S., Ben-Menachem, T., Vasudevan, G., Ma, C.K. and Blumenkehl, M. (1999) Prospective Evaluation of Unexplained Chronic Liver Transaminase Abnormalities in Asymptomatic and Symptomatic Patients. American Journal of Gastroenterology, 94, 3010-3014. https://doi.org/10.1111/j.1572-0241.1999.01451.x
|
[15]
|
de Castro, M.L., Hermo, J.A. and Baz, A. (2006) Acute Cholestatic Hepatitis after Atorvastatin Reintroduction. Gastroenterología y Hepatología, 29, 21-24. https://doi.org/10.1157/13083248
|
[16]
|
Patti, G., Cannon, C.P., Murphy, S.A., Mega, S., Pasceri, V., Briguori, C., et al. (2011) Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. Circulation, 123, 1622-1632. https://doi.org/10.1161/CIRCULATIONAHA.110.002451
|
[17]
|
Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H., Burke, M., Davey Smith, G., et al. (2013) Statins for the Primary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews, 2013, CD004816. https://doi.org/10.1002/14651858.CD004816.pub5
|
[18]
|
Fallo, F., Dalla Pozza, A. and Tecchio, M. (2010) Non-Alcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study. American Journal of Hypertension, 23, 2-5. https://doi.org/10.1038/ajh.2009.206
|
[19]
|
Adachi, Y., Bradford, B.U., Gao, W., Bojes, H.K. and Thurman, R.G. (1994) The Activation of Kupffer Cells Prevents Early Alcohol-Induced Liver Injury. Hepatology, 20, 453-460. https://doi.org/10.1002/hep.1840200227
|
[20]
|
Adachi, Y., Moore, L.E., Bradford, B.U., Gao, W. and Thurman, R.G. (1995) Antibiotics Prevent Liver Injury in Rats Following Long-Term Exposure to Ethanol. Gastroenterology, 108, 218-224. https://doi.org/10.1016/0016-5085(95)90027-6
|
[21]
|
Tilg, H., Jalan, R., Kaser, A., Davies, N.A., Offner, F.A., Hodges, S.J., et al. (2003) Anti-Tumor Necrosis Factor-Alpha Monoclonal Antibody Therapy in Severe Alcoholic Hepatitis. Journal of Hepatology, 38, 419-425. https://doi.org/10.1016/S0168-8278(02)00442-7
|
[22]
|
Hashimoto, E., Yatsuji, S., Kaneda, H., Yoshioka, Y., Taniai, M., Tokushige, K., et al. (2005) The Characteristics and Natural History of Japanese Patients with Non-Alcoholic Fatty Liver Disease. Hepatology Research, 33, 72-76.
|
[23]
|
Hritz, I., Mandrekar, P., Velayudham, A., Catalano, D., Dolganiuc, A., Kodys, K., et al. (2008) The Critical Role of Toll-Like Receptor (TLR) 4 in Alcoholic Liver Disease Is Independent of the Standard TLR Adapter MyD88. Hepatology, 48, 1224-1231. https://doi.org/10.1002/hep.22470
|
[24]
|
Mandrekar, P. and Szabo, G. (2009) Signaling Pathways in Alcohol-Induced Liver Inflammation. Journal of Hepatology, 50, 1258-1266. https://doi.org/10.1016/j.jhep.2009.03.007
|
[25]
|
Wolters, L.M.M and Van Buuren, H.R. (2005) Rosuvastatin-Associated Hepatitis with Autoimmune Features. European Journal of Gastroenterology and Hepatology, 17, 589-590. https://doi.org/10.1097/00042737-200505000-00019
|
[26]
|
Diehl, A.M. (2001) Non-Alcoholic Fatty Liver Disease: Implications for Alcoholic Liver Disease Pathogenesis. Alcoholism: Clinical and Experimental Research, 25, 8S-14S. https://doi.org/10.1111/j.1530-0277.2001.tb02368.x
|
[27]
|
Nakad, A., Bataille, L., Hamoir, V., Sempoux, C. and Horsmans, Y. (1999) Atorvastatin-Induced Acute Hepatitis with No Cross-Toxicity with the Simvastatin. Lancet, 353, 1763-1764. https://doi.org/10.1016/S0140-6736(99)00569-3
|
[28]
|
Vernon, G., Baranova, A. and Younossi, Z.M. (2011) Systematic Review: The Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in Adults. Alimentary Pharmacology and Therapeutics, 34, 274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
|
[29]
|
Karlmark, K.R., Wasmuth, H.E., Trautwein, C. and Tacke, F. (2008) Chemokine-Directed Immune Cell Infiltration in Acute and Chronic Liver Disease. Expert Revue of Gastroenterology & Hepatology, 2, 233-242. https://doi.org/10.1586/17474124.2.2.233
|
[30]
|
Seki, E., de Minicis, S., Inokuchi, S., Taura, K., Miyai, K., van Rooijen, N., et al. (2009) CCR2 Promotes Hepatic Fibrosis in Mice. Hepatology, 185, 185-197. https://doi.org/10.1002/hep.22952
|
[31]
|
Sheng, Z., Otani, H., Brown, M.S. and Goldstein, J.L. (1995) Independent Regulation of Sterol Regulatory Element-Binding Proteins 1 and 2 in Hamster Liver. Proceedings of the National Academy of Sciences of the United States of America, 92, 935-938. https://doi.org/10.1073/pnas.92.4.935
|
[32]
|
Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., et al. (2007) Prevalence of Non-Alcoholic Fatty Liver Disease: A Population-Based Study. Annals of Hepatology, 6, 161-163. https://doi.org/10.1016/S1665-2681(19)31922-2
|
[33]
|
Li, H., Wang, Y.J., Tan, K., Zeng, L., Liu, L., Liu, F.J., et al. (2009) Prevalence and Risk Factors of Fatty Liver Disease in Chengdu, Southwest China. Hepatobiliary & Pancreatic Diseases International, 8, 377-382.
|
[34]
|
Pasternak, R.C., Smith Jr., S.C., Bairey-Merz, C.N., Grundy, S.M., Cleeman, J.I. and Lenfant, C. (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 106, 1024-1028. https://doi.org/10.1161/01.CIR.0000032466.44170.44
|
[35]
|
Frith, J., Day, C.P., Henderson, E., Burt, A.D. and Newton, J.L. (2009) Non-Alcoholic Fatty Liver Disease in Older People. Gerontology, 55, 607-613. https://doi.org/10.1159/000235677
|
[36]
|
Kagansky, N., Levy, S., Keter, D., Rimon, E., Taiba, Z., Fridman, Z., et al. (2004) Non-Alcoholic Fatty Liver Disease—A Common and Benign Finding in Octogenarian Patients. Liver International, 24, 588-594. https://doi.org/10.1111/j.1478-3231.2004.0969.x
|
[37]
|
Kichian, K., McLean, R., Gramlich, L.M., Bailey, R.J. and Bain, V.G. (2003) Non-Alcoholic Fatty Liver Disease in Patients Investigated for Elevated Liver Enzymes. Canadian Journal of Gastroenterology and Hepatology, 17, Article ID: 268528. https://doi.org/10.1155/2003/268528
|
[38]
|
Park, S.H., Jeon, W.K.., Kim, S.H., Kim, H.J., Park, D.I., Cho, Y.K., et al. (2006) Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease among Korean Adults. Journal of Gastroenterology and Hepatology, 21, 138-143. https://doi.org/10.1111/j.1440-1746.2005.04086.x
|
[39]
|
Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. (2005) The Natural History of Non-Alcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology, 129, 113-121. https://doi.org/10.1053/j.gastro.2005.04.014
|
[40]
|
Askgaard, G., Gronbaek, M., Kjaer, M.S., Tjonneland, A. and Tolstrup, J.S. (2015) Alcohol Drinking Pattern and Risk of Alcoholic Liver Cirrhosis: A Prospective Cohort study. Journal of Hepatology, 62, 1061-1067. https://doi.org/10.1016/j.jhep.2014.12.005
|
[41]
|
Ascha, M.S., Hanouneh, I.A., Lopez, R., Tamimi, T.A., Feldstein, A.F. and Zein, N.N. (2010) The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis. Hepatology, 51, 1972-1978. https://doi.org/10.1002/hep.23527
|
[42]
|
Hashimoto, E., Yatsuji, S., Tobari, M., Taniai, M., Torii, N., Tokushige, K., et al. (2009) Hepatocellular Carcinoma in Patients with Non-Alcoholic Steatohepatitis. Journal of Gastroenterology, 44, 89-95. https://doi.org/10.1007/s00535-008-2262-x
|
[43]
|
Lee, J.Y., Kim, K.M. and Lee, S.G. (2007) Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Potential Living Liver Donors in Korea: A Review of 589 Consecutive Liver Biopsies in a Single Center. Journal of Hepatology, 47, 239-244. https://doi.org/10.1016/j.jhep.2007.02.007
|
[44]
|
Goldstein, J.L. and Brown, M.S. (2015) A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell, 161, 161-172. https://doi.org/10.1016/j.cell.2015.01.036
|
[45]
|
Leite, N.C., Salles, G.F., Araujo, A.L., Villela-Nogueira, C.A. and Cardoso, C.R. (2009) Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Liver International, 29, 113-119. https://doi.org/10.1111/j.1478-3231.2008.01718.x
|
[46]
|
Seki, E., De Minicis, S., Gwak, G.Y., Kluwe, J., Inokuchi, S., Bursill, C.A., et al. (2009) CCR1 and CCR5 Promote Hepatic Fibrosis in Mice. Journal of Clinical Investigation, 119, 1858-1870. https://doi.org/10.1172/JCI37444
|
[47]
|
Szabo, G. and Dolganiuc, A. (2006) Mandrekar Pattern Recognition Receptors: A Contemporary View on Liver Diseases. Hepatology, 44, 287-298. https://doi.org/10.1002/hep.21308
|
[48]
|
Donohue Jr., T.M., Osna, N.A., Trambly, C.S., Whitaker, N.P., Thomes, P.G., Todero, S.L., et al. (2012) Early Growth Response-1 Contributes to Steatosis Development after Acute Ethanol Administration. Alcoholism: Clinical and Experimental Research, 36, 759-767. https://doi.org/10.1111/j.1530-0277.2011.01681.x
|
[49]
|
Ruhl, C.E. and Everhart, J.E. (2005) Joint Effects of Body Weight and Alcohol on Elevated Serum Alanine Aminotransferase in the United States Population. Clinical Gastroenterology and Hepatology, 3, 1260-1268. https://doi.org/10.1016/S1542-3565(05)00743-3
|
[50]
|
Kotronen, A., Johansson, L.E., Johansson, L.M., Roos, C., Westerbacka, J., Hamsten, A., et al. (2009) A Common Variant in PNPLA3, Which Encodes Adiponutrin, Is Associated with Liver Fat Content in Humans. Diabetologia, 52, 1056-1060. https://doi.org/10.1007/s00125-009-1285-z
|
[51]
|
Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. (2010) Pioglitazone, Vitamin E or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 362, 1675-1685. https://doi.org/10.1056/NEJMoa0907929
|
[52]
|
Fan, J.G., Zhu, J., Li, X.J., Chen, L., Li, L., Dai, F., et al. (2005) Prevalence of and Risk Factors for Fatty Liver in a General Population of Shanghai, China. Journal of Hepatology, 43, 508-514. https://doi.org/10.1016/j.jhep.2005.02.042
|
[53]
|
Kim, H.J., Kim, H.J., Lee, K.E., Kim, D.J., Kim, S.K., Ahn, C.W., et al. (2004) Metabolic Significance of Non-Alcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults. Archives of Internal Medicine, 164, 2169-2175. https://doi.org/10.1001/archinte.164.19.2169
|
[54]
|
Ong, J.P., Pitts, A. and Younossi, Z.M. (2008) Increased Mortality and Liver-Related Mortality in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 49, 608-612. https://doi.org/10.1016/j.jhep.2008.06.018
|
[55]
|
Sookoian, S. and Priola, C.J. (2011) Meta-Analysis of the Influence of the I148M Variant of Patatin-Like Phospholipase Domain-Containing Three-Gene (PNPLA3) on the Susceptibility and Histological Severity of the Non-Alcoholic Fatty Liver Disease. Hepatology, 53, 1883-1894. https://doi.org/10.1002/hep.24283
|
[56]
|
Chen, Z.W., Chen, L.Y., Dai, H.L., Chen, J.H. and Fang, L.Z. (2008) Relation between Alanine Aminotransferase Levels and Metabolic Syndrome in Non-Alcoholic Fatty Liver Disease. Journal of Zhejiang University SCIENCE B, 9, Article No. 616. https://doi.org/10.1631/jzus.B0720016
|
[57]
|
Souza, M.R., DinizMde, F., Medeiros-Filho, J.E. and Trigueiro de Araújo, M.S. (2012) Metabolic Syndrome and Risk Factors for Non-Alcoholic Fatty Liver Disease. Arquivos de Gastroenterologia, 49, 89-96. https://doi.org/10.1590/S0004-28032012000100015
|
[58]
|
Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., et al. (2006) Reevaluation of Serum Alanine Amino-Transferase Normal Upper Limits and Modulating Factors in a Large-Scale Population Study. Liver International, 26, 445-450. https://doi.org/10.1111/j.1478-3231.2006.01197.x
|
[59]
|
Prashanth, M., Ganesh, H.K. and Vima, M.V. (2009) Prevalence of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Journal of the Association of Physicians of India, 57, 205-210.
|
[60]
|
Frazier, T.H., Stocker, A.M., Kershner, N.A., Marsano, L.S. and McClain, C.J. (2011) Treatment of Alcoholic Liver Disease. Therapeutic Advances in Gastroenterology, 4, 63-81. https://doi.org/10.1177/1756283X10378925
|
[61]
|
Schierwagen, R., Maybüchen, L., Zimmer, S., Hittatiya, K., B?ck, C., Klein, S., et al. (2015) Seven Weeks of Western diet in Apolipoprotein-E-Deficient Mice Induce Metabolic Syndrome and Non-Alcoholic Steatohepatitis with Liver Fibrosis. Scientific Reports, 5, Article No. 12931. https://doi.org/10.1038/srep12931
|
[62]
|
Baranova, A., Tran, T.P., Birerdinc, A. and Younossi, Z.M. (2011) Systematic Review: Association of Polycystic Ovary Syndrome with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 33, 801-814. https://doi.org/10.1111/j.1365-2036.2011.04579.x
|
[63]
|
Gambarin-Gelwan, M., Kinkhabwala, S.V., Schiano, T.D., Bodian, C., Yeh, H.C. and Fut-Terweit, W. (2007) Prevalence of Non-Alcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Clinical Gastroenterology and Hepatology, 5, 496-501. https://doi.org/10.1016/j.cgh.2006.10.010
|
[64]
|
Cerda, C., Pérez-Ayuso, R.M. and Riquelme, A. (2007) Non-Alcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome. Journal of Hepatology, 47, 412-417. https://doi.org/10.1016/j.jhep.2007.04.012
|
[65]
|
Hossain, N., Stepanova, M., Afendy, A., Nader, F., Younossi, Y., Rafiq, N., et al. (2011) Non-Alcoholic Steatohepatitis (NASH) Patients with the Polycystic Ovarian Syndrome (PCOS). Scandinavian Journal of Gastroenterology 46, 479-484. https://doi.org/10.3109/00365521.2010.539251
|
[66]
|
Crum-Cianflone, N, Dilay, A., Collins, G., Asher, D., Campin, R., Medina, S., et al. (2009) Non-Alcoholic Fatty Liver Disease among HIV-Infected Persons. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50, 464-473. https://doi.org/10.1097/QAI.0b013e318198a88a
|
[67]
|
Wrenn, K.D. and Slovis, C.M. (1992) Is Intravenous Thiamine Safe? The American Journal of Emergency Medicine, 10, 165. https://doi.org/10.1016/0735-6757(92)90054-2
|
[68]
|
Guaraldi, G., Squillace, N.., Stentarelli, C., Orlando, G., D’Amico, R., Ligabue, G., et al. (2008) Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. Clinical Infectious Diseases, 47, 250-257. https://doi.org/10.1086/589294
|
[69]
|
Teli, M.R., Day, C.P, Burt, A.D. and Bennett, M.K. (1995) Determinants of Progression to Cirrhosis or Fibrosis in Pure Alcoholic Fatty Liver. Lancet, 346, 987-990. https://doi.org/10.1016/S0140-6736(95)91685-7
|
[70]
|
Singal, A.K., Chaha, K.S., Rasheed, K. and Anand, B.S. (2013) Liver Transplantation in Alcoholic Liver Disease Current Status and Controversies. World Journal of Gastroenterology, 19, 5953-5963. https://doi.org/10.3748/wjg.v19.i36.5953
|
[71]
|
Zakhari, S. and Li, T.K. (2007) Determinants of Alcohol Use and Abuse: Impact of Quantity and Frequency Patterns on Liver Disease. Hepatology, 46, 2032-2039. https://doi.org/10.1002/hep.22010
|
[72]
|
Jimenez-Alonso, J., Osorio, J.M., Gutierrez-Cabello, F., López de la Osa, A., León, L. and Mediavilla García, J.D. (1999) Atorvastatin-Induced Cholestatic Hepatitis in a Young Woman with Systemic Lupus Erythematosus. Grupo Lupus Virgen de las Nieves. Archives of Internal Medicine, 159, 1811-1812.
|
[73]
|
Lefkowitch, J.H. (2005) Morphology of Alcoholic Liver Disease. Clinics in Liver Disease, 9, 37-53. https://doi.org/10.1016/j.cld.2004.11.001
|
[74]
|
Yu, A.S. and Keeffe, E.B. (2003) Elevated AST or ALT to Non-Alcoholic Fatty Liver Disease: An Accurate Predictor of Disease Prevalence? American Journal of Gastroenterology, 98, 955-956. https://doi.org/10.1111/j.1572-0241.2003.07485.x
|
[75]
|
Chong, L.-W., Hsu, Y.-C., Lee, T.-F., Lin, Y., Chiu, Y.T., Yang, K.C., et al. (2015) Fluvastatin Attenuates Hepatic Steatosis-Induced Fibrogenesis in Rats through Inhibiting Paracrine Effect of Hepatocyte on Hepatic Stellate Cells. BMC Gastroenterology, 15, Article No. 22. https://doi.org/10.1186/s12876-015-0248-8
|
[76]
|
Marrone, G., Russo, L., Rosado, E., Hide D, García-Carde?a, G., García-Pagán, J.C., et al. (2013) The Transcription Factor KLF2 Mediates Hepatic Endothelial Protection and Paracrine Endothelial-Stellate Cell Deactivation Induced by Statins. Journal of Hepatology, 58, 98-103. https://doi.org/10.1016/j.jhep.2012.08.026
|
[77]
|
Chang, C.Y. and Schiano, T.D. (2007) Revue Article: Drug Hepatotoxicity. Alimentary Pharmacology and Therapeutics, 25, 1135-1151. https://doi.org/10.1111/j.1365-2036.2007.03307.x
|
[78]
|
Dujovne, C.A. (2002) Side Effects of Statins: Hepatitis versus “Transaminitis”-Myositis versus “CPKitis”. American Journal of Cardiology, 89, 1411-1413. https://doi.org/10.1016/S0002-9149(02)02356-1
|
[79]
|
Alla, V., Abraham, J., Siddiqui, J., Raina, D., Wu, G.Y., Chalasani, N.P., et al. (2006) Autoimmune Hepatitis Triggered by Statins. Journal of Clinical Gastroenterology, 40, 757-761. https://doi.org/10.1097/00004836-200609000-00018
|
[80]
|
Graziadei, I.W., Obermoser, G.E., Sepp, N.T., Erhart, K.H. and Vogel, W. (2003) Drug-Induced, a Lupus-Like Syndrome Associated with Severe Autoimmune Hepatitis. Lupus, 12, 409-412. https://doi.org/10.1191/0961203303lu313cr
|
[81]
|
Pignatelli, P., Carnevale, R., Pastori, D., Cangemi, R., Napoleone, L., Bartimoccia, S., et al. (2012) Immediate Antioxidant, and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2. Circulation, 126, 92-103. https://doi.org/10.1161/CIRCULATIONAHA.112.095554
|
[82]
|
Becker, U., Deis, A., Sorensen, T.I.A., Gronbaek, M., Borch-Johnsen, K., Muller, C.F., et al. (1996) Prediction of Risk of Liver Disease by Alcohol Intake, Sex, and Age: A Prospective Population Study. Hepatology, 23, 1025-1029. https://doi.org/10.1002/hep.510230513
|
[83]
|
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y. and Patra, J. (2009) Global Burden of Disease and Injury and Economic Cost Attributable to Alcohol Use and Alcohol-Use Disorders. Lancet, 373, 2223-2233. https://doi.org/10.1016/S0140-6736(09)60746-7
|
[84]
|
Galli, A., Pinaire, J., Fischer, M., Dorris, R. and Crabb, D.W. (2001) The Transcriptional and DNA Binding Activity of Peroxisome Proliferator-Activated Receptor Alpha Is Inhibited by Ethanol Metabolism: A Novel Mechanism for the Development of Ethanol-Induced Fatty Liver. Journal of Biological Chemistry, 276, 68-75. https://doi.org/10.1074/jbc.M008791200
|
[85]
|
McClain, C.J., Song, Z., Barve, S.S., Hill, D.B. and Deaciuc, I. (2004) Recent Advances in Alcoholic Liver Disease: IV. Dysregulated Cytokine Metabolism in Alcoholic Liver Disease. American Journal of Physiology-Gastrointestinal and Liver Physiology, 287, G497-G502. https://doi.org/10.1152/ajpgi.00171.2004
|
[86]
|
Bellentani, S. and Tiribelli, C. (2001) The Spectrum of Liver Disease in the General Population: Lesson from the Dionysos Study. Journal of Hepatology, 35, 531-537. https://doi.org/10.1016/S0168-8278(01)00151-9
|
[87]
|
Garbutt, J.C., West, S.L., Carey, T.S., Lohr, K.N. and Crews, F.T. (1999) Pharmacological Treatment of Alcohol Dependence. JAMA, 281, 1318-1325. https://doi.org/10.1001/jama.281.14.1318
|
[88]
|
Wilfred de Alwis, N.M. and Day, C.P. (2007) Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 27, 44-54. https://doi.org/10.1055/s-2006-960170
|
[89]
|
Grove, J., Brown, A.S., Daly, A.K., James, O., Day, C.P. and Brown, A. (1998) The RSAI Polymorphism of CYP2E1 and Susceptibility to Alcoholic Liver Disease in Caucasians: Effect on Age of Presentation and Dependence on Alcohol Dehydrogenase Genotype. Pharmacogenetics, 8, 335-342. https://doi.org/10.1097/00008571-199808000-00007
|
[90]
|
Bays, H., Cohen, D.E., Chalasani, N. and Harrison, S.A. (2014) An Assessment by the Statin Liver Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S47-S57. https://doi.org/10.1016/j.jacl.2014.02.011
|
[91]
|
Fattaccioli, V., Andraud, E., Gentil, M., French, S.W. and Rouach, H. (1999) Effects of Ethanol Administration on Rat Liver Protease Activities: Relationship with Oxidative Stress. Hepatology, 29, 14-20. https://doi.org/10.1002/hep.510290106
|
[92]
|
Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al. (2010) Safety and Efficacy of Long-Term Statin Treatment for Cardiovascular Events in Patients with Coronary Heart Disease and Abnormal Liver Tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREECE) Study: A Posthoc Analysis. Lancet, 376, 1916-1922. https://doi.org/10.1016/S0140-6736(10)61272-X
|
[93]
|
Lewis, J.H., Mortensen, M.E., Zweig, S., Fusco, M.J., Medoff, J.R. and Belder, R. (2007) Efficacy and Safety of High-Dose Pravastatin in Hypercholesterolemic Patients with Well-Compensated Chronic Liver Disease: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Hepatology, 46, 1453-1463. https://doi.org/10.1002/hep.21848
|
[94]
|
Piton, A., Poynard, T., Imbert-Bismuth, F., Khalil, L., Delattre, J., Pelissier, E., et al. (1998) Factors Associated with Serum Alanine Transaminase Activity in Healthy Subjects: Consequences for the Definition of Average Values for Selecting Blood Donors, and Patients with Chronic hepatitis C. MULTIVIRC Group. Hepatology, 27, 1213-1219. https://doi.org/10.1002/hep.510270505
|
[95]
|
WagenKnecht, L.E., Scherzinger, A.L., Stamm, E.R., Hanley, A.J., Norris, J.M., Chen, Y.-D.I., et al. (2009) Correlates and Heritability of Non-Alcoholic Fatty Liver Disease in a Minority Cohort. Obesity, 17, 1240-1246. https://doi.org/10.1038/oby.2009.4
|
[96]
|
Del Ben, M., Polimeni, L., Carnevale, R., Bartimoccia, S., Nocella, C., Baratta, F., et al. (2014) NOX2-Generated Oxidative Stress Is Associated with the Severity of Ultrasound Liver Steatosis in Patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology, 14, Article No. 81. https://doi.org/10.1186/1471-230X-14-81
|
[97]
|
Schwimmer, J.B., Celedon, M.A., Lavine, J.E., Salem, R., Campbell, N., Schork, N.J., et al. (2009) Heritability of Non-Alcoholic Fatty Liver Disease. Gastroenterology, 136, 1585-1592. https://doi.org/10.1053/j.gastro.2009.01.050
|
[98]
|
Tanaka, K., Tokunaga, S., Kono, S., Tokudome, S., Akamatsu, T., Moriyama, T., et al. (1998) Coffee Consumtion and Decreased Serum Gamma-Glutamyltransferase and Aminotransferase Activities among Male Alcohol Drinkers. International Journal of Epidemiology, 27, 438-443. https://doi.org/10.1093/ije/27.3.438
|
[99]
|
Athyros, V.G., Mikhailidis, D.P., Didangelos, T.P., Giouleme, O.I., Liberopoulos, E.N., Karagiannis, A., et al. (2006) Effect of Multifactorial Treatment on Non-Alcoholic Fatty Liver Disease in Metabolic Syndrome: A Randomized Study. Current Medical Research and Opinion, 22, 873-883. https://doi.org/10.1185/030079906X104696
|
[100]
|
Wheeler, M.D., Kono, H., Yin, M., Nakagami, M., Uesugi, T., Arteel, G.E, et al. (2001) The Role of Kupffer Cell Oxidant Production in Early Ethanol-Induced Liver Disease. Free Radical Biology and Medicine, 31, 1544-1549. https://doi.org/10.1016/S0891-5849(01)00748-1
|
[101]
|
Foster, T., Budoff, M.J., Saab, S., Ahmadi, N., Gordon, C. and Guerci, AD. (2011) Atorvastatin and Antioxidants for Treating Non-Alcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial. American Journal of Gastroenterology, 106, 71-77. https://doi.org/10.1038/ajg.2010.299
|
[102]
|
Roglans, N., Verd, J.C., Peris, C., Alegret, M., Vazquez, M., Adzet, T., et al. (2002) High Doses of Atorvastatin and Simvastatin Impel Critical Enzymes Involved in VLDL Production. Lipids, 37, 445-454. https://doi.org/10.1007/s11745-002-0916-0
|
[103]
|
Aubert, J., Begriche, K., Knockaert, L., Robin, M.A. and Fromenty, B. (2011) Increased Expression of Cytochrome P450 2E1 in Non-Alcoholic Fatty Liver Disease: Mechanisms and Pathophysiological Role. Clinics and Research in Hepatology and Gastroenterology, 35, 630-637. https://doi.org/10.1016/j.clinre.2011.04.015
|
[104]
|
Wang, W., Zhao, C., Zhou, J., Zhen, Z., Wang, Y. and Shen, C. (2013) Simvastatin Ameliorates Liver Fibrosis via Mediating Nitric Oxide Synthase in Rats with Non-Alcoholic Steatohepatitis-Related Liver Fibrosis. PLOS ONE, 8, e76538. https://doi.org/10.1371/journal.pone.0076538
|